Publications by authors named "N van der Veen"
Background: In community-acquired pneumonia (CAP), the role of biomarkers to shorten duration of antibiotic treatment has not been firmly established. We assessed the effectiveness of active feedback of treatment algorithms based on procalcitonin (PCT) and C-reactive protein (CRP), compared to standard care, on the duration of antibiotic treatment in patients hospitalized with community-acquired pneumonia (CAP) in non-ICU wards.
Methods And Findings: We performed a randomised, open label, parallel group, multi-centre trial in 3 Dutch teaching hospitals.
Background: Cognitive deficits may be characteristic for only a subgroup of first-episode psychosis (FEP) and the link with clinical and functional outcomes is less profound than previously thought. This study aimed to identify cognitive subgroups in a large sample of FEP using a clustering approach with healthy controls as a reference group, subsequently linking cognitive subgroups to clinical and functional outcomes.
Methods: 204 FEP patients were included.
Article Synopsis
- The study aims to provide a thorough, evidence-based overview of Achilles tendinopathy, focusing on risk factors, prevention, diagnosis, treatment, and prognosis, while offering clinical recommendations for practitioners and patients.
- The guideline process involved input from patients at every stage and included comprehensive research from multiple databases and stakeholder feedback up to May 2019.
- Six modules were developed covering key areas including risk factors, diagnosis, and treatment, leading to targeted recommendations based on both literature and patient input.
Objective: Immune dysregulation may be involved in the pathophysiology of schizophrenia. Given the need for new treatment options in schizophrenia, anti-inflammatory medication could be a potential treatment in this illness.
Methods: In this double-blind, placebo-controlled clinical trial, patients with schizophrenia, schizoaffective disorder or psychosis NOS were randomized 1:1 to either prednisolone or placebo, in addition to their regular antipsychotic medication.
In their landmark report on the "Principles and Practice of Screening for Disease" (1968), Wilson and Jungner noted that the practice of screening is just as important for securing beneficial outcomes and avoiding harms as the formulation of principles. Many jurisdictions have since established various kinds of "screening governance organizations" to provide oversight of screening practice. Yet to date there has been relatively little reflection on the nature and organization of screening governance itself, or on how different governance arrangements affect the way screening is implemented and perceived and the balance of benefits and harms it delivers.
View Article and Find Full Text PDF